B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
Asis Shrestha,
Marah Alzubi,
Jawad Alrawabdeh,
Carolina Schinke,
Sharmilan Thanendrarajan,
Maurizio Zangari,
Frits vanRhee,
Samer Al Hadidi
Affiliations
Asis Shrestha
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Marah Alzubi
Department of Medicine, School of Medicine University of Jordan Amman Jordan
Jawad Alrawabdeh
Department of Medicine, School of Medicine University of Jordan Amman Jordan
Carolina Schinke
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Sharmilan Thanendrarajan
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Maurizio Zangari
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Frits vanRhee
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Samer Al Hadidi
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA
Abstract Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow‐up was 9.5 months (range: 6–24 months). The median progression free survival was 5.5 months (range: 1–10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell‐associated neurotoxicity syndrome. Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.
